Loading…

Cost-Consequence Analysis of Using Neurofarmagen In The Decision-Making Process During The Treatment of Patients With Depression In The U.S

OBJECTIVES: Almost half of U.S. population has experienced at least one psychiatric disorder in their lifetime, being major depression (MD) the most common among these illnesses. MD is highly debilitating to society, due in part to the increased utilization of health care resources and their associa...

Full description

Saved in:
Bibliographic Details
Published in:Value in health 2017-10, Vol.20 (9), p.A713
Main Authors: Espadaler, J, Carcedo, D, Pérez-Mitru, A, Menchón, J, Saiz-Ruiz, J, Bobes, J, Vieta, E, Alvarez, E, Pérez, V
Format: Article
Language:English
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page
container_issue 9
container_start_page A713
container_title Value in health
container_volume 20
creator Espadaler, J
Carcedo, D
Pérez-Mitru, A
Menchón, J
Saiz-Ruiz, J
Bobes, J
Vieta, E
Alvarez, E
Pérez, V
description OBJECTIVES: Almost half of U.S. population has experienced at least one psychiatric disorder in their lifetime, being major depression (MD) the most common among these illnesses. MD is highly debilitating to society, due in part to the increased utilization of health care resources and their associated cost and to frequent suboptimal treatment responses. The aim of this study is to compare the cost and consequences of using the Neuropharmagen® (NFG) pharmacogenetic tool in the decision-making process of treating depression relapsed patients in the U.S. METHODS: A decision-tree model was developed in order to estimate the cost and consequences of using NFG over a 3-year time horizon. Model compared NFG testing-guided treatment vs. treatment as usual (TaU) in MD patients who had not responded to 1-3 previous treatment(s). Treatment response and stabilization rates were obtained from the 3-months assessment reported in the prospective randomized controlled trial of NFG and extrapolated up to 1 year. For "responder" patients, yearly relapse rate of 0.2 was considered. "Non-responder" and relapsed patients progressed to the next treatment line. The model considered direct costs (2017 US$) for "responder" and "non-responder" patients obtained from published literature RESULTS: In patients with 1-3 prior treatment failures, total management costs per patient (responder and non-responder) after 1 and 3 years were $1,307 and $4,172 lower in NFG testing-guided treatment compared with TaU respectively, not counting testing cost. 67.1% more patients achieved treatment response in NFG testing-guided treatment compared with TaU already first year (TaU response rate = 31.0%). Scenarios including other patient subgroups were tested, and one-way sensitivity analysis confirmed the robustness of these results CONCLUSIONS: In patients with 1 to 3 prior treatments, NFG testing-guided treatment of patients with MD will represent a cost-saving option vsTAU after 1 year. After 3-year time horizon, the analysis showed considerable savings
doi_str_mv 10.1016/j.jval.2017.08.1891
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2113725462</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2113725462</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1171-c23bad0b360ddf39d64b538783ed5ff19e6e8aa58943d2f78ce7362c0bd4ef953</originalsourceid><addsrcrecordid>eNo1kF1LwzAYhYsoOKe_wJuA1635aNr0cnR-DKYO3PAyZOmbrXVLZtIK-w3-aVumV-954TkHzomiW4ITgkl23yTNt9olFJM8wSIhoiBn0YhwmsZpzth5r3EhYoYJv4yuQmgwxhmjfBT9lC60celsgK8OrAY0sWp3DHVAzqBVqO0GvULnnVF-rzZg0cyi5RbQFHQdamfjF_U5QAvvNISApp0f3gFZelDtHmw7RC1UW_cyoI-63fbug-_p3v-ft0rer6MLo3YBbv7uOFo9PizL53j-9jQrJ_NYE5KTWFO2VhVeswxXlWFFlaVrzkQuGFTcGFJABkIpLoqUVdTkQkPOMqrxukrBFJyNo7tT7sG7vnRoZeM639cOkhLCcsrTjPYUO1HauxA8GHnw9V75oyRYDqvLRg6ry2F1iYUcVme_oEx38Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2113725462</pqid></control><display><type>article</type><title>Cost-Consequence Analysis of Using Neurofarmagen In The Decision-Making Process During The Treatment of Patients With Depression In The U.S</title><source>Applied Social Sciences Index &amp; Abstracts (ASSIA)</source><source>Elsevier</source><creator>Espadaler, J ; Carcedo, D ; Pérez-Mitru, A ; Menchón, J ; Saiz-Ruiz, J ; Bobes, J ; Vieta, E ; Alvarez, E ; Pérez, V</creator><creatorcontrib>Espadaler, J ; Carcedo, D ; Pérez-Mitru, A ; Menchón, J ; Saiz-Ruiz, J ; Bobes, J ; Vieta, E ; Alvarez, E ; Pérez, V</creatorcontrib><description>OBJECTIVES: Almost half of U.S. population has experienced at least one psychiatric disorder in their lifetime, being major depression (MD) the most common among these illnesses. MD is highly debilitating to society, due in part to the increased utilization of health care resources and their associated cost and to frequent suboptimal treatment responses. The aim of this study is to compare the cost and consequences of using the Neuropharmagen® (NFG) pharmacogenetic tool in the decision-making process of treating depression relapsed patients in the U.S. METHODS: A decision-tree model was developed in order to estimate the cost and consequences of using NFG over a 3-year time horizon. Model compared NFG testing-guided treatment vs. treatment as usual (TaU) in MD patients who had not responded to 1-3 previous treatment(s). Treatment response and stabilization rates were obtained from the 3-months assessment reported in the prospective randomized controlled trial of NFG and extrapolated up to 1 year. For "responder" patients, yearly relapse rate of 0.2 was considered. "Non-responder" and relapsed patients progressed to the next treatment line. The model considered direct costs (2017 US$) for "responder" and "non-responder" patients obtained from published literature RESULTS: In patients with 1-3 prior treatment failures, total management costs per patient (responder and non-responder) after 1 and 3 years were $1,307 and $4,172 lower in NFG testing-guided treatment compared with TaU respectively, not counting testing cost. 67.1% more patients achieved treatment response in NFG testing-guided treatment compared with TaU already first year (TaU response rate = 31.0%). Scenarios including other patient subgroups were tested, and one-way sensitivity analysis confirmed the robustness of these results CONCLUSIONS: In patients with 1 to 3 prior treatments, NFG testing-guided treatment of patients with MD will represent a cost-saving option vsTAU after 1 year. After 3-year time horizon, the analysis showed considerable savings</description><identifier>ISSN: 1098-3015</identifier><identifier>EISSN: 1524-4733</identifier><identifier>DOI: 10.1016/j.jval.2017.08.1891</identifier><language>eng</language><publisher>Lawrenceville: Elsevier Science Ltd</publisher><subject>Chronic illnesses ; Clinical trials ; Counting ; Decision making ; First year ; Health care expenditures ; Help seeking behavior ; Illnesses ; Medical treatment ; Mental depression ; Patients ; Relapse ; Response rates ; Robustness ; Savings ; Sensitivity analysis ; Stabilization ; Tau protein</subject><ispartof>Value in health, 2017-10, Vol.20 (9), p.A713</ispartof><rights>Copyright Elsevier Science Ltd. Oct/Nov 2017</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27922,27923,30997</link.rule.ids></links><search><creatorcontrib>Espadaler, J</creatorcontrib><creatorcontrib>Carcedo, D</creatorcontrib><creatorcontrib>Pérez-Mitru, A</creatorcontrib><creatorcontrib>Menchón, J</creatorcontrib><creatorcontrib>Saiz-Ruiz, J</creatorcontrib><creatorcontrib>Bobes, J</creatorcontrib><creatorcontrib>Vieta, E</creatorcontrib><creatorcontrib>Alvarez, E</creatorcontrib><creatorcontrib>Pérez, V</creatorcontrib><title>Cost-Consequence Analysis of Using Neurofarmagen In The Decision-Making Process During The Treatment of Patients With Depression In The U.S</title><title>Value in health</title><description>OBJECTIVES: Almost half of U.S. population has experienced at least one psychiatric disorder in their lifetime, being major depression (MD) the most common among these illnesses. MD is highly debilitating to society, due in part to the increased utilization of health care resources and their associated cost and to frequent suboptimal treatment responses. The aim of this study is to compare the cost and consequences of using the Neuropharmagen® (NFG) pharmacogenetic tool in the decision-making process of treating depression relapsed patients in the U.S. METHODS: A decision-tree model was developed in order to estimate the cost and consequences of using NFG over a 3-year time horizon. Model compared NFG testing-guided treatment vs. treatment as usual (TaU) in MD patients who had not responded to 1-3 previous treatment(s). Treatment response and stabilization rates were obtained from the 3-months assessment reported in the prospective randomized controlled trial of NFG and extrapolated up to 1 year. For "responder" patients, yearly relapse rate of 0.2 was considered. "Non-responder" and relapsed patients progressed to the next treatment line. The model considered direct costs (2017 US$) for "responder" and "non-responder" patients obtained from published literature RESULTS: In patients with 1-3 prior treatment failures, total management costs per patient (responder and non-responder) after 1 and 3 years were $1,307 and $4,172 lower in NFG testing-guided treatment compared with TaU respectively, not counting testing cost. 67.1% more patients achieved treatment response in NFG testing-guided treatment compared with TaU already first year (TaU response rate = 31.0%). Scenarios including other patient subgroups were tested, and one-way sensitivity analysis confirmed the robustness of these results CONCLUSIONS: In patients with 1 to 3 prior treatments, NFG testing-guided treatment of patients with MD will represent a cost-saving option vsTAU after 1 year. After 3-year time horizon, the analysis showed considerable savings</description><subject>Chronic illnesses</subject><subject>Clinical trials</subject><subject>Counting</subject><subject>Decision making</subject><subject>First year</subject><subject>Health care expenditures</subject><subject>Help seeking behavior</subject><subject>Illnesses</subject><subject>Medical treatment</subject><subject>Mental depression</subject><subject>Patients</subject><subject>Relapse</subject><subject>Response rates</subject><subject>Robustness</subject><subject>Savings</subject><subject>Sensitivity analysis</subject><subject>Stabilization</subject><subject>Tau protein</subject><issn>1098-3015</issn><issn>1524-4733</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>7QJ</sourceid><recordid>eNo1kF1LwzAYhYsoOKe_wJuA1635aNr0cnR-DKYO3PAyZOmbrXVLZtIK-w3-aVumV-954TkHzomiW4ITgkl23yTNt9olFJM8wSIhoiBn0YhwmsZpzth5r3EhYoYJv4yuQmgwxhmjfBT9lC60celsgK8OrAY0sWp3DHVAzqBVqO0GvULnnVF-rzZg0cyi5RbQFHQdamfjF_U5QAvvNISApp0f3gFZelDtHmw7RC1UW_cyoI-63fbug-_p3v-ft0rer6MLo3YBbv7uOFo9PizL53j-9jQrJ_NYE5KTWFO2VhVeswxXlWFFlaVrzkQuGFTcGFJABkIpLoqUVdTkQkPOMqrxukrBFJyNo7tT7sG7vnRoZeM639cOkhLCcsrTjPYUO1HauxA8GHnw9V75oyRYDqvLRg6ry2F1iYUcVme_oEx38Q</recordid><startdate>201710</startdate><enddate>201710</enddate><creator>Espadaler, J</creator><creator>Carcedo, D</creator><creator>Pérez-Mitru, A</creator><creator>Menchón, J</creator><creator>Saiz-Ruiz, J</creator><creator>Bobes, J</creator><creator>Vieta, E</creator><creator>Alvarez, E</creator><creator>Pérez, V</creator><general>Elsevier Science Ltd</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7QJ</scope></search><sort><creationdate>201710</creationdate><title>Cost-Consequence Analysis of Using Neurofarmagen In The Decision-Making Process During The Treatment of Patients With Depression In The U.S</title><author>Espadaler, J ; Carcedo, D ; Pérez-Mitru, A ; Menchón, J ; Saiz-Ruiz, J ; Bobes, J ; Vieta, E ; Alvarez, E ; Pérez, V</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1171-c23bad0b360ddf39d64b538783ed5ff19e6e8aa58943d2f78ce7362c0bd4ef953</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Chronic illnesses</topic><topic>Clinical trials</topic><topic>Counting</topic><topic>Decision making</topic><topic>First year</topic><topic>Health care expenditures</topic><topic>Help seeking behavior</topic><topic>Illnesses</topic><topic>Medical treatment</topic><topic>Mental depression</topic><topic>Patients</topic><topic>Relapse</topic><topic>Response rates</topic><topic>Robustness</topic><topic>Savings</topic><topic>Sensitivity analysis</topic><topic>Stabilization</topic><topic>Tau protein</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Espadaler, J</creatorcontrib><creatorcontrib>Carcedo, D</creatorcontrib><creatorcontrib>Pérez-Mitru, A</creatorcontrib><creatorcontrib>Menchón, J</creatorcontrib><creatorcontrib>Saiz-Ruiz, J</creatorcontrib><creatorcontrib>Bobes, J</creatorcontrib><creatorcontrib>Vieta, E</creatorcontrib><creatorcontrib>Alvarez, E</creatorcontrib><creatorcontrib>Pérez, V</creatorcontrib><collection>CrossRef</collection><collection>Applied Social Sciences Index &amp; Abstracts (ASSIA)</collection><jtitle>Value in health</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Espadaler, J</au><au>Carcedo, D</au><au>Pérez-Mitru, A</au><au>Menchón, J</au><au>Saiz-Ruiz, J</au><au>Bobes, J</au><au>Vieta, E</au><au>Alvarez, E</au><au>Pérez, V</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cost-Consequence Analysis of Using Neurofarmagen In The Decision-Making Process During The Treatment of Patients With Depression In The U.S</atitle><jtitle>Value in health</jtitle><date>2017-10</date><risdate>2017</risdate><volume>20</volume><issue>9</issue><spage>A713</spage><pages>A713-</pages><issn>1098-3015</issn><eissn>1524-4733</eissn><abstract>OBJECTIVES: Almost half of U.S. population has experienced at least one psychiatric disorder in their lifetime, being major depression (MD) the most common among these illnesses. MD is highly debilitating to society, due in part to the increased utilization of health care resources and their associated cost and to frequent suboptimal treatment responses. The aim of this study is to compare the cost and consequences of using the Neuropharmagen® (NFG) pharmacogenetic tool in the decision-making process of treating depression relapsed patients in the U.S. METHODS: A decision-tree model was developed in order to estimate the cost and consequences of using NFG over a 3-year time horizon. Model compared NFG testing-guided treatment vs. treatment as usual (TaU) in MD patients who had not responded to 1-3 previous treatment(s). Treatment response and stabilization rates were obtained from the 3-months assessment reported in the prospective randomized controlled trial of NFG and extrapolated up to 1 year. For "responder" patients, yearly relapse rate of 0.2 was considered. "Non-responder" and relapsed patients progressed to the next treatment line. The model considered direct costs (2017 US$) for "responder" and "non-responder" patients obtained from published literature RESULTS: In patients with 1-3 prior treatment failures, total management costs per patient (responder and non-responder) after 1 and 3 years were $1,307 and $4,172 lower in NFG testing-guided treatment compared with TaU respectively, not counting testing cost. 67.1% more patients achieved treatment response in NFG testing-guided treatment compared with TaU already first year (TaU response rate = 31.0%). Scenarios including other patient subgroups were tested, and one-way sensitivity analysis confirmed the robustness of these results CONCLUSIONS: In patients with 1 to 3 prior treatments, NFG testing-guided treatment of patients with MD will represent a cost-saving option vsTAU after 1 year. After 3-year time horizon, the analysis showed considerable savings</abstract><cop>Lawrenceville</cop><pub>Elsevier Science Ltd</pub><doi>10.1016/j.jval.2017.08.1891</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1098-3015
ispartof Value in health, 2017-10, Vol.20 (9), p.A713
issn 1098-3015
1524-4733
language eng
recordid cdi_proquest_journals_2113725462
source Applied Social Sciences Index & Abstracts (ASSIA); Elsevier
subjects Chronic illnesses
Clinical trials
Counting
Decision making
First year
Health care expenditures
Help seeking behavior
Illnesses
Medical treatment
Mental depression
Patients
Relapse
Response rates
Robustness
Savings
Sensitivity analysis
Stabilization
Tau protein
title Cost-Consequence Analysis of Using Neurofarmagen In The Decision-Making Process During The Treatment of Patients With Depression In The U.S
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T21%3A08%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cost-Consequence%20Analysis%20of%20Using%20Neurofarmagen%20In%20The%20Decision-Making%20Process%20During%20The%20Treatment%20of%20Patients%20With%20Depression%20In%20The%20U.S&rft.jtitle=Value%20in%20health&rft.au=Espadaler,%20J&rft.date=2017-10&rft.volume=20&rft.issue=9&rft.spage=A713&rft.pages=A713-&rft.issn=1098-3015&rft.eissn=1524-4733&rft_id=info:doi/10.1016/j.jval.2017.08.1891&rft_dat=%3Cproquest_cross%3E2113725462%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c1171-c23bad0b360ddf39d64b538783ed5ff19e6e8aa58943d2f78ce7362c0bd4ef953%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2113725462&rft_id=info:pmid/&rfr_iscdi=true